Journal Article

Lipid predictors of coronary heart disease and tibolone users

D. Crook

in European Heart Journal Supplements

Volume 3, issue suppl_M, pages M22-M26
Published in print October 2001 | ISSN: 1520-765X
Published online October 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90079-3
Lipid predictors of coronary heart disease and tibolone users

Show Summary Details

Preview

Tibolone reduces plasma levels of total cholesterol by approximately 5%, triglycerides by approximately 25% and lipoprotein(a) by 20–30%, with little effect on the levels of low-density lipoproteins. In contrast to these theoretical beneficial effects, there is a 20–30% fall in levels of high-density lipoproteins (HDL). The failure of recent placebocontrolled clinical trials of hormone replacement therapy to show a cardiovascular benefit with elevated HDL levels raises the possibility that hormone replacement therapy-induced plasma lipid changes may not accurately predict clinical events. Advances in our understanding of lipoprotein metabolism, especially resulting from identification of new receptors, challenge the conventional belief that reducing HDL levels will cause cardiovascular disease.

Keywords: Coronary heart disease; high-density lipoprotein; hormone replacement therapy; lipids; tibolone

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.